Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for th… Read more
Market Cap & Net Worth: Cingulate Inc (CING)
Cingulate Inc (NASDAQ:CING) has a market capitalization of $87.95 Million ($87.95 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20941 globally and #7549 in its home market, demonstrating a 2.16% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cingulate Inc's stock price $8.04 by its total outstanding shares 10938733 (10.94 Million).
Cingulate Inc Market Cap History: 2021 to 2026
Cingulate Inc's market capitalization history from 2021 to 2026. Data shows change from $7.25 Billion to $87.95 Million (-68.12% CAGR).
Index Memberships
Cingulate Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.00% | #567 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #1881 of 3165 |
Weight: Cingulate Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cingulate Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cingulate Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CING by Market Capitalization
Companies near Cingulate Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Cingulate Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Cingulate Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Cingulate Inc's market cap moved from $7.25 Billion to $ 87.95 Million, with a yearly change of -68.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $87.95 Million | +85.25% |
| 2025 | $47.47 Million | -11.97% |
| 2024 | $53.93 Million | -94.63% |
| 2023 | $1.00 Billion | -61.75% |
| 2022 | $2.63 Billion | -63.77% |
| 2021 | $7.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Cingulate Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $87.95 Million USD |
| MoneyControl | $87.95 Million USD |
| MarketWatch | $87.95 Million USD |
| marketcap.company | $87.95 Million USD |
| Reuters | $87.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.